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Even though human hookworm infection is highly endemic in many countries throughout
the world, its global economic and health impact is not well known. Without a better under-
standing of hookworm’s economic burden worldwide, it is difficult for decision makers such
as funders, policy makers, disease control officials, and intervention manufacturers to deter-
mine how much time, energy, and resources to invest in hookworm control.
Methodology/Principle Findings
We developed a computational simulation model to estimate the economic and health bur-
den of hookworm infection in every country, WHO region, and globally, in 2016 from the
societal perspective. Globally, hookworm infection resulted in a total 2,126,280 DALYs
using 2004 disability weight estimates and 4,087,803 DALYs using 2010 disability weight
estimates (excluding cognitive impairment outcomes). Including cognitive impairment did
not significantly increase DALYs worldwide. Total productivity losses varied with the proba-
bility of anemia and calculation method used, ranging from $7.5 billion to $138.9 billion
annually using gross national income per capita as a proxy for annual wages and ranging
from $2.5 billion to $43.9 billion using minimum wage as a proxy for annual wages.
Conclusion
Even though hookworm is classified as a neglected tropical disease, its economic and
health burden exceeded published estimates for a number of diseases that have received
comparatively more attention than hookworm such as rotavirus. Additionally, certain large
countries that are transitioning to higher income countries such as Brazil and China, still
face considerable hookworm burden.
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Author Summary
Our work quantifies the economic and health burden associated with hookworm infection
by country, WHO region, and worldwide. We also evaluated the burden by age, various
costing methodologies, and ran an extensive sensitivity analysis on key and debated
parameters to determine the robustness of our model’s resulting estimates. We report the
DALYs associated with hookworm infections with consequent health outcomes in 2016
and show the impact that varying disability weights and likelihoods of anemia have on the
estimates. Additionally, our study identified potential targets for future studies and data
collection. Our results provide important information for decision makers. Without a bet-
ter understanding of the economic and health burden of hookworm worldwide and in dif-
ferent countries, it is difficult for decision makers such as funders, policy makers, disease
control officials, and intervention manufacturers to determine how much time, energy,
and resources to invest in hookworm control. Our results can also help decision makers
know where hookworm should fall on their priority lists and allocate limited resources.
Introduction
Even though human hookworm infection (hookworm) is highly endemic in many low- and
middle-income countries throughout the world, its global economic and health impact is not
well known. Unlike other soil-transmitted helminth (STH) infections (e.g., ascariasis and tri-
churiasis), high intensity hookworm infection commonly affects both children and adults.[1, 2]
Hookworm is typically controlled through mass drug administration (MDA) programs. While
these programs have successfully reduced morbidity due to STHs among children, it is not hav-
ing a similar effect on hookworm. In fact, MDA with mebendazole is not reducing the preva-
lence of hookworm-related anemia[3], while the impact of MDA with albendazole in children
is inconsistent[4, 5]. Moreover, the Global Burden of Disease (GBD) Study 2013 estimates that
MDA is not having a significant effect in reducing in the prevalence of hookworm infection.[6]
Even when MDA programs are in place they primarily target pre-school and school-aged chil-
dren[7, 8], leaving high-burden groups untreated.
Despite these control programs, hookworm’s disease burden remains high, currently, hook-
worm affects approximately 500 million people[6], with 5.1 billion at risk for acquiring infec-
tion worldwide.[9] However, hookworm infection rarely results in death, but instead leads to
iron-deficiency anemia and malnutrition[10], which cause more subtle chronic health prob-
lems such as lethargy, impaired physical and cognitive development, and adverse pregnancy
outcomes[1]. Therefore, measures that focus on severe disease outcomes such as mortality and
hospitalization will severely underestimate the economic and health burden of hookworm.
Moreover, those infected with hookworm may have concomitant health conditions, such as
malaria infection, that can also cause anemia.[11] Without a better understanding of the eco-
nomic and health burden of hookworm worldwide and in different countries, it is difficult for
decision makers such as funders, policy makers, disease control officials, and intervention
manufacturers to determine how much time, energy, and resources to invest in hookworm
control. Therefore, we developed a computational simulation model to meet this need.
Methods
Model Structure
Using Microsoft Excel (Microsoft, Redmond, WA) along with a Crystal Ball (Oracle, Redwood
City, CA) add-in, we developed a Monte Carlo simulation model to determine the economic
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and health burden of hookworm infection by country (N = 159, all countries where prevalence
is reported and transmission is viable), WHO region, and worldwide from the societal perspec-
tive. The model converted age-specific hookworm prevalence and population estimates of dif-
ferent locations into hookworm cases by age, determined the intensity level of each hookworm
infection, converted each case into health outcomes, and translated health outcomes into pro-
ductivity losses and disability-adjusted life years (DALYs).
The model starts with age-stratified hookworm prevalence estimates by location, using the
following age strata (i): children 0–4 years old, 5–9 years old, 10–14 years old, and adults 15
years and older. We determined the infection intensity level by calculating the mean worm bur-
den (M, average number of worms per person) of the age-stratified population from the preva-
lence and applied a negative binomial distribution of worms in the community[12] resulting in
the probability of an individual harboring a given number of worms. The negative binomial
distribution allowed us to represent the over-dispersion of worms, such that a few individuals
harbor most of the worms. The model estimated M based on the hookworm prevalence (P) for
each age-specific population using the following equation:






derived from Anderson and May[12], where k is the degree of aggregation of worms within the
human population (where the proportion of the human population harboring the majority of
hookworms becomes smaller as k approaches 0), and was set at 0.34.[13, 14] We calculated the
probability of low (<28 worms), moderate (28–65 worms), and heavy intensity (>65 worms)
infection[15] by fitting M to the negative binomial distribution:
Pix ¼ 1þ Mi=k
 kx Mi=k x Г k þ xð Þx!Г xð Þ
 
where Г() is a gamma distribution and x is the number of worms. These probabilities multi-
plied by the total population determined the number of persons in each age group with each
infection intensity level (i.e., number of persons with low, moderate, or heavy intensity infec-
tions in each age group).
Our model then converted each hookworm infection into health outcomes (i.e., hookworm-
associated anemia and cognitive impairment) with accompanying health effects and costs.
Each person with a hookworm infection had a probability of having hookworm-associated ane-
mia. We derived the probability of hookworm-associated anemia using the age-stratified, infec-
tion intensity-specific probability of anemia and population attributable fraction (PAF). Age-
and intensity-specific probabilities of anemia among those with hookworm infection came
from the literature (Table 1). While there is a direct relationship between the intensity of hook-
worm infection (i.e., number of adult worms inside the host) and host blood loss[16], hook-
worm is not the only cause of anemia. We used the PAF, or the proportion of anemia in the
population that is due to hookworm (Table 1), to attenuate the probabilities of anemia to deter-
mine the probability of hookworm-associated anemia. Each person with anemia then had a
probability of having a specific hemoglobin (Hb) level. This probability was pulled from an
age- and infection intensity-specific distribution. The distribution of Hb levels for each infec-
tion intensity level and age group was custom and created using data extracted from the litera-
ture on Hb levels for those with anemia and a hookworm infection.[16–21] As infants and
children are particularly vulnerable to developmental and behavioral deficits, most likely due
to iron-deficiency anemia[1], only children (0–14 years old) with anemia due to moderate and
heavy intensity infections were assumed to have cognitive impairment.
Global Economic Burden of Hookworm
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Health effects were measured in DALYs, which are the sum of the years of life lived with dis-
ability (YLD) and the years of life lost (YLL). However, since hookworm rarely causes death
directly, our DALY calculation formula did not include YLLs and was therefore:
DALY ¼ YLD ¼ IDWL
where I is the number of incident cases, DW is the disability weight, and L is the average dura-
tion of the outcome (Table 1). YLDs accrued from anemia, heavy hookworm infection (>65
worms), and cognitive impairment (when included). The DW varied by the level of anemia
depending on the scenario. As we aim to estimate the annual burden of hookworm, we
assumed the duration of each outcome (i.e., hookworm-associated anemia and cognitive
impairment) to be one year. Due to a lack of data on this outcome, we feel this is a conservative
estimate given many people with hookworm would not receive treatment that would impact
the duration of anemia or intensity of infection (e.g., annual MDA or iron-supplements); addi-
tionally, many studies looking at productivity losses evaluated a yearlong period[22].
Since a majority of infected individuals do not seek medical care for hookworm infection,
our model did not include direct healthcare costs and instead focused on lost productivity (i.e.,
societal perspective). We assumed productivity losses accrue for all ages. To account for











Anemia (2004 Estimate) 0.024 [49]
Heavy Intensity Infection (2004 Estimate) 0.006 [49]
Cognitive Impairment (2004 Estimate)ǂ 0.024 0.024 [49]
Mild Anemia (2010 Estimate)† 0.005 (0.002–
0.011)
[50]
Moderate Anemia (2010 Estimate)† 0.058 (0.0380–
0.086)
[50]
Severe Anemia (2010 Estimate)† 0.164 (0.112–
0.228)
[50]
Symptomatic Intestinal Nematode Infections
(2010 Estimate)†^
0.03 (0.016–0.048) [50]
Duration of Anemia (years) 1 Assumption




Low Estimate Study 0.129 0.133 0.143 [19]
Median Estimate Study 0.088 0.182 0.182 [18]
High Estimate Study 0.600 0.737 0.797 [17]
Adults
Low Estimate Study 0.041 0.100 0.045 [18]
Median Estimate Study 0.486 0.610 0.720 [30]
High Estimate Study 0.697 0.740 0.803 [16]
*Mean (standard deviation), beta distribution
ǂOnly children aged 0–14 years with anemia due to moderate or high intensity infections were assumed to have cognitive impairment
†Estimate (95% uncertainty interval), triangular distribution
^Used for heavy intensity infections only
doi:10.1371/journal.pntd.0004922.t001
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potential variability in assigning productivity reductions due to anemia, different scenarios
explored the impact of using the following methodologies for estimating productivity losses for
each person with hookworm-associated anemia (summarized in Table 2). The first method
applied the DW for anemia to individual productivity for the duration of anemia (one year):
Productivity Losses ¼ Per Capita Productivity  DW  L ð1Þ
where the DW served as a proxy for the reduction in productivity and varied by the level of
anemia, depending on the analysis scenario. Anemia levels were defined as: mild anemia 11–
12.5g/dL for adults and 11g/dL for children, moderate anemia 8–10.9g/dL for all ages, and
severe anemia<8g/dL for all ages.[23, 24] Productivity losses for individuals with heavy inten-
sity infection and cognitive impairment were also considered using this method, using their
respective DW estimates.
The second method is based on the reduction in productivity due to anemia using methods
described by Shastry andWeil.[25] This productivity reduction was calculated from an individ-
ual’s Hb level and determined the level of productivity in workers with anemia relative to those
without anemia. The following formula calculated productivity losses using this method:




where 1.5 is the elasticity of productivity with respect to blood Hb among anemic workers.[25]
Elasticity is the percent change in work capacity or output divided by percent change in Hb;
thus, for every 1% increase in Hb levels, there will be a 1.5% increase in output. We used ane-
mia thresholds of 12.5g/dL for adults and 11g/dL for children.[24]
The third method was adapted from a study on the economic impact of anemia in Peru[26]
(which is based on a model by Ross and Horton[27]). This method calculates the cost due to
productivity losses as:
Productivity Losses
¼ Loss of Productivity  Wage Share  Gross Domestic Product per Capita  Prevalence
where loss of productivity is the loss of productivity for an adult with anemia; wage share is the
ratio of employee compensation over the Gross Domestic Product (GDP) per capita; and preva-
lence is the prevalence of anemia in the population. As this formula results in the productivity loss
per capita in the population due to anemia, we modified it to calculate the cost for an individual.
Wage share and GDP per capita can be simplified to wage per capita; thus we used per capita
Table 2. Summary of methods used to estimate productivity losses.
Method Formula* Assumptions Sources
1 Productivity Losses = Per Capita Productivity x
Disability Weight x Duration
Disability weight serves as a proxy for reductions in productivity.
2 Productivity Losses = Per Capita Productivity x (1-
(Hemoglobin Level/Anemia Threshold)1.5)
Reductions in productivity due to anemia are determined from individual’s
hemoglobin level relative to those without anemia. Elasticity of 1.5 estimates the
change in work capacity or output divided by percent change in hemoglobin.
[25]
3 Productivity Losses = Per Capita Productivity x
Loss of Productivity
Adapted from study on economic impact of anemia in a population and modified
for an individual, assumes a 5% loss of productivity regardless of age.
[26, 27]
*Per capita productivity = a person’s median productivity contributions to society
doi:10.1371/journal.pntd.0004922.t002
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productivity. Our modified formula is:
Productivity Losses ¼ Loss of Productivity  Per Capita Productivity ð3Þ
Previous work has estimated the loss of productivity in adults with anemia doing manual
labor that is not highly demanding (e.g., technical staff, salespersons, etc.) to be 5% and those
with highly demanding physical work (e.g., laborers or agricultural workers) to be 12–17%.[26]
A systematic review estimated the percent of annual productivity loss for anemia due to soil-
transmitted helminths ranged from 0.1% to 17%.[22] To remain conservative, we utilized 5%
for all ages and did not stratify by work force type.
Data Sources
Table 1 shows our overall model inputs while S1 Table provides country-specific values. The
United Nations 2015 population estimates supplied the population size by age group.[28]
Country-specific, age-stratified hookworm prevalence estimates consisted of a triangular prev-
alence distribution for each of the four modeled age groups.[29] We assumed the prevalence of
hookworm has not changed substantially over time, given prevalence has only decreased 5%
between 1990 and 2013.[6] The probability of anemia by hookworm infection intensity and by
age group (children and adults) came from the literature.[16–19, 30] Depending on the sce-
nario, gross national income (GNI) per capita or minimum wage served as a proxy for a per-
son’s median productivity contributions to society (i.e., per capita productivity), but does not
necessarily reflect that actual income of each person, which may be significantly less in impov-
erished areas. GNI per capita was obtained from the World Bank[31], supplemented with data
from the United Nations[32] when not available from the World Bank. For the 14 countries
for which GNI per capita was not available from either source, we utilized the average GNI
from similar countries in the same region (defined by income classification when available or
similar economies and industries). Minimum wage data was obtained from the US Department
of State.[33] Again, for countries in which data was not available (31 countries), we utilized the
average minimum wage from similar countries in the same region. All costs are presented in
2016 US dollars, converted using a 3% discount rate. DW values for hookworm and hook-
worm-associated health outcomes came from published estimates (Table 1).
Simulation Scenarios
For each scenario, we ran 1,000 Monte Carlo simulations varying parameters throughout their
ranges and report the median and 95% uncertainty interval (UI). Sensitivity analysis explored
the impact of varying the following parameters: estimates for the probability of anemia for a
given intensity of hookworm infection for children and adults (low, median, and high estimates
from different studies in the literature, Table 1), the DW values (range: 2004 GBD estimates to
the 2010 GBD estimates and additionally +/-10% of each of these two sets of estimates), the
presence/absence of cognitive impairment, and annual wages (county-specific GNI per capita
and minimum wage data). Additional scenarios evaluated the thresholds for low (<50 worms),
moderate (50–105 worms), and heavy intensity (>105 worms) infection.[34]
Results
Health Effects as Measured by DALYs
Table 3 presents the number of hookworm infections with consequent health outcomes (i.e.,
those with heavy intensity infection and hookworm-associated anemia,) and total DALYs
accrued for each region and worldwide in 2016 (excluding cognitive impairment) using the
Global Economic Burden of Hookworm
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Table 3. Total annual hookworm-associated anemia cases and hookworm infections with consequent health outcomes, disability-adjusted life
years (DALYs), and costs [median (95% uncertainty interval), in millions] due to hookworm infection by global region and worldwide in 2016 with-
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2004 DW estimates. The total number of DALYs varied with the probability of anemia given
hookworm infection. Globally, 88,801,614 heavy hookworm infections and hookworm-associ-
ated anemia cases resulted in 2,126,280 DALYs (95% UI: 1,105,778–3,408,973), assuming the
median likelihood of anemia. This translates to an average 0.0239 DALYs accrued (95% UI:
0.0150–0.0459 DALYs) annually per hookworm infection with consequent health outcomes.
The Western Pacific region accrued the most DALYs. Including cognitive impairment
increased the total DALYs accrued worldwide to 2,126,469 (95% UI: 1,105,873–3,409,135).
Table 4 shows the DALYs accrued when using the 2010 DW estimates. This method resulted
in an estimated 4,087,803 DALYs globally (95% UI: 386,827–17,054,291, median likelihood of
anemia). Fig 1A shows how sensitive our DALY estimates are to the DW utilized (2004, 2010,
and varying both by +/-10%) with the width of the bar indicating the range of total DALYs
accrued across the varying likelihoods of anemia for each DW estimate evaluated. The 2010
DWs resulted in substantially more DALYs accrued than the 2004 DWs.
Global DALY estimates did not differ substantially when varying the infection intensity
threshold. Threshold of 1 to 49, 50 to 104, and105 worms resulted in 89,765,729 infections
with consequent health outcomes globally. These infections generated 2,091,209 (95% UI:
1,105,275–3,462,856) DALYs using the 2004 DW estimates and 4,193,001 (95% UI: 395,922–
16,499,971) DALYs using the 2010 DW estimates (median likelihood of anemia).
Costs (Productivity Losses)
Table 3 also provides the productivity losses for hookworm-associated anemia in 2016 esti-
mated from the three different calculation methods. Hookworm resulted in $11.0 billion (95%
UI: $5.7–17.9 billion) in productivity losses (Method 1, median likelihood of anemia). Method
2, based on Hb levels, resulted in higher productivity losses overall, ranging from $56.8 to
$138.9 billion annually, varying with the likelihood of anemia. Method 3 also resulted in higher
productivity losses, ranging from $16.9 to 36.3 billion, depending on the likelihood of anemia.
As Method 1 is more conservative (i.e., results in the lower economic burden) and more inclu-
sive in health outcomes (i.e., includes infection, anemia, and cognitive impairment), the rest of
the results utilized this method.
Including the cognitive impairment outcome had little effect on total costs. Inclusion
increased global costs by approximately $650,000, $1.2 million, and $4.3 million annually for
low, median, and high likelihoods of anemia, respectively. None of these increases resulted in
significantly different global cost estimates. Differences were primarily seen in the African














































Note: Hb = hemoglobin; DW = disability weight
aIncludes outcomes of anemia and heavy intensity infection
doi:10.1371/journal.pntd.0004922.t003
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Fig 1. Impact of disability weight (DW) estimates on A) global DALYs, and B) global productivity losses across varying levels
of anemia calculated using Method 1 (including cognitive impairment). The lower end of the range is the total burden assuming a
Global Economic Burden of Hookworm
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Globally, total productivity losses were sensitive to the DWs utilized when calculating costs
via Method 1 (Fig 1B). Although there was some overlap between cost estimates, substantial
variability arose when using the 2010 DW values, especially across the different likelihoods of
anemia. A 10% increase in the 2010 DW values with a high likelihood of anemia resulted in
productivity losses of $38.2 billion annually worldwide. Using the 2010 DW estimates substan-
tially increased the economic burden of hookworm (Table 4). Assuming a median likelihood of
anemia, hookworm cost $20.9 billion (95% UI: $1.8–89.1 billion) worldwide. The low estimate
for anemia yielded $11.2 billion (95% UI: $1.6–83.1 billion) in total costs.
Using minimum wage data as a proxy for per capita productivity, hookworm results in pro-
ductivity losses totaling $2.5 to $5.4 billion using Method 1 and 2004 DW estimates, $3.4 to
$10.5 billion using Method 1 and 2010 DW estimates, $17.5 to $43.9 billion using Method 2,
and $5.1 to $11.3 billion using Method 3, varying with the likelihood of anemia (low to high).
Fig 2 shows how the burden estimates differ by region, annual wage, and productivity loss
method used. In most regions, using the GNI per capita resulted in a burden 1.8 to 2.7 times
higher (depending on the region) than when using the minimum wage, regardless of the calcu-
lation method, with the exception the Western Pacific, where estimates using GNI per capita
were 4.0 fold higher than using minimum wage.
The cost per hookworm infection with consequent health outcomes (i.e., heavy intensity
infection, hookworm-associated anemia, and cognitive impairment) is an estimated $56 (95%
UI: $52–59) in Africa, $215 (95% UI: $203–227) in the Americas, $86 (95% UI: $80–94) in the
Eastern Mediterranean, $202 (95% UI: $184–216) in Europe, $48 (95% UI: $45–51) in South
East Asia, and $183 (95% UI: $178–187) in the Western Pacific (Method 1, median likelihood
of anemia, 2004 DW estimates, GNI per capita). Using the 2010 DW estimates, these increased
to $120 (95% UI: $24–415) in Africa, $447 (95% UI: $40–1,693) in the Americas, $176 (95%
UI: $17–672) in the Eastern Mediterranean, $406 (95% UI: $20–1,595) in Europe, $99 (95%
UI: $9–370) in South East Asia, and $375 (95% UI: $30–1,414) in the Western Pacific. Using
minimum wage as a proxy for per capita productivity, the cost per hookworm infection is an
estimated $24 (95% UI: $23–25) in Africa, $82 (95% UI: $77–89) in the Americas, $47 (95%
UI: $45–50) in the Eastern Mediterranean, $80 (95% UI: $71–87) in Europe, $25 (95% UI:
$24–26) in South East Asia, and $45 (95% UI: $44–45) in the Western Pacific (using 2004 DW
estimates). There is considerable variation in different countries due to per capita productivity
proxy assumed (GNI per capita vs. minimum wage), DW estimates used (2004 vs. 2010), and
variations in the 2010 DW estimates.
A closer look at individual countries shows that China’s 35,917,360 hookworm infections
with consequent health outcomes result in $6.7 billion in productivity losses using GNI per
capita, $1.7 billion in productivity losses using minimum wage, and 862,017 DALYs annually.
In India, 11,781,041 hookworm-associated health outcomes cost $471 million (GNI per capita;
$258 million using minimum wage) with 282,75 DALYs lost. Brazil’s estimated 1,355,874
infections with consequent health outcomes cost $398 million and $80 million in productivity
losses using GNI per capita and minimum wage, respectively (and 32,541 DALYs) annually. In
Africa, Nigeria harbors the largest hookworm burden with 3,738,750 infections with conse-
quent health outcomes costing $283 million using GNI per capita and $99 million using mini-
mum wage, and accruing 89,730 DALYs.
Again, results were robust to changes in the infection intensity threshold. Assuming a
median likelihood of anemia, 2004 DW estimates, and GNI per capita, 89,765,729 hookworm
low probability of anemia, while the upper end assumed a high probability of anemia. The 2004 DW and 2010 DW represent results with
the published DW estimates and +/- 10% indicates adjustment to these values.
doi:10.1371/journal.pntd.0004922.g001
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infections that accrue health outcomes globally resulted in productivity losses totaling $11.1
billion (95% UI: $5.5–18.5 billion) utilizing Method 1, $87.9 billion (95% UI: $1.7–302.3 bil-
lion) utilizing Method 2, and $23.1 (95% UI: $11.4–38.4 billion) utilizing Method 3. Using
minimum wage, the global burden calculated using Method 1 was $3.3 billion (2004 DW
Table 4. Total annual hookworm-associated anemia cases and hookworm infections with consequent health outcomes, disability-adjusted life
years (DALYs), and costs [median (95% uncertainty interval), in millions] due to hookworm infection by global region and worldwide in 2016 using
the 2010 disability weight estimates and GNI per capita as a proxy for annual wages.
Number with Hookworm-
Associated Anemia
Number Hookworm Infections with
Consequent Health Outcomes





14,508,448 (3,714,312–37,616,985) 594,303 (136,519–
3,475,798)
1,442 (414–7,748)
Americas 2,768,102 (464,302–8,217,664) 2,782,924 (437,366–8,055,027) 96,333 (12,925–715,775) 849 (112–6,493)
Eastern
Mediterranean
1,135,944 (199,126–3,286,609) 1,121,787 (198,913–3,260,959) 40,326 (6,215–291,279) 138 (20–1,019)
Europe 12,414 (1,034–37,289) 12,043 (1,048–37,555) 355 (9–3421) 3 (0–27)
South-East Asia 15,289,602 (2,547,997–
44,979,096)
14,900,576 (2,546,556–42,332,600) 535,843 (75,011–
3,754,327)
1,065 (144–7,493)
Western Pacific 30,736,718 (4,284,618–
92,737,620)






















1,551,203 (757,976–2,477,911) 1,520,231 (796,265–2,564,340) 71,290 (6,520–290,076) 256 (21–1,040)
Europe 17,420 (8,232–27,665) 17,388 (8,846–29,932) 786 (35–3,360) 6 (0–28)
South-East Asia 20,627,972 (10,326,213–
33,725,352)
20,510,540 (10,602,277–34,437,672) 970,366 (81,755–
3,834,583)
1,955 (158–7,678)
Western Pacific 42,528,706 (20,207,813–
71,510,519)


























2,647,969 (1,391,489–4,217,500) 120,864 (24,791–
465,864)
419 (80–1,604)
Europe 25,053 (12,842–43,202) 25,223 (12,738–41,219) 1,068 (58–4,933) 9 (0–41)
South-East Asia 3,517,1442 (18,608,681–
57,235,451)
34,987,826 (17,894,163–56,186,335) 1,573,595 (295,314–
5,911,227)
3,112 (571–11,854)
Western Pacific 68,095,564 (33,944,724–
118,129,017)










Note: Hb = hemoglobin; DW = disability weight
aIncludes outcomes of anemia and heavy intensity infection
doi:10.1371/journal.pntd.0004922.t004
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Fig 2. Hookworm-associated productivity losses in 2016 by annual wage proxy used for A) Africa, B) the Americas, C) Eastern
Mediterranean, D) Europe, E) South-East Asia, and F) Western Pacific regions.
doi:10.1371/journal.pntd.0004922.g002
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estimates) and $6.5 billion (2010 DW estimates); using Method 2 and 3, productivity losses
totaled $25.1 billion and $6.8 billion, respectively.
Discussion
Even though hookworm is classified as a neglected tropical disease, its economic and health
burden (ranging from $7.5 billion to $138.9 billion using GNI per capita and ranging from $2.4
billion to $43.9 billion using minimum wage) exceeded published estimates for a number of
diseases that have received comparatively more attention than hookworm. For example, rotavi-
rus cost an estimated $423 million ($262–590 million) to society in low- and middle-income
countries in the absence of vaccination (2007 values)[35], and $2 billion annually globally
(2007 values).[36] Annual estimates for tuberculosis suggest $12 billion in productivity losses
alone (assuming a 30% reduction in productivity and loss of 15 income years per death).[37]
Dengue cost an estimated $12.3 billion worldwide in 2010.[38] Although the general method-
ologies of these studies are similar (identifying the number of cases and associated unit costs),
caution should be taken when making direct comparisons as there is variation in specific costs
included. Our study shows how the cumulative economic impact of a subacute chronic disease
like hookworm can eventually exceed the impact of diseases that have higher mortality and
more salient health effects.
Quantifying the economic burden of a disease can help aid decision makers, such as funding
agencies and public health bodies, make informed decisions about where to best allocate lim-
ited resources and gauge investments and potential returns for intervention and control mea-
sures. Showing the burden can also tell investors and manufacturers, how much can be
invested in prevention and control strategies, and provide motivation for research and develop-
ment of new strategies (e.g., vaccines). These investments can not only improve the health of
those with hookworm, but support the economic growth of affected regions as they become
more economically productive.
Our study also identified potential targets for future studies and data collection. These are
parameters whose values substantially influence the burden estimates. Our results were sensi-
tive to the disability weights used, the calculation method used to determine productivity losses
due to anemia, and the probability of hookworm-associated anemia (which likely varies across
regions). Variability in these parameters, along with differences in outcomes included and
methodologies to attribute Hb levels, account for differences between our DALY estimates and
those published by the GBD. The revised GBD study for 2010 reports the loss of 3,230,800
DALYs annually due to hookworm among all ages in 21 regions.[29] This estimate included
disability weights for additional hookworm outcomes (wasting and mild abdominopelvic prob-
lems) and stratified by level of anemia, but did not include cognitive impairment.
Another finding is that certain large countries that are transitioning to higher income coun-
tries such Brazil and China, still face considerable hookworm burden. These countries are
investing heavily in infrastructure and various industries but it is not clear how much they may
be spending on controlling hookworm.
All models are simplifications of real life[39] and therefore cannot represent every possible
hookworm event or outcome. Other diseases occurring in the same geographic area cause ane-
mia and cognitive impairment (e.g., malaria, schistosomiasis, and meningitis), which may
make it difficult to attribute the true underlying cause and infected individuals may not seek
care or be appropriately diagnosed.[40] Data used in our model came from a variety of sources
and studies of variable quality; therefore our results may change as more data becomes avail-
able. For example, hookworm prevalence data is limited; it tends to be extrapolated from local-
ized cross-sectional surveys, many of which are done in high prevalence areas with differing
Global Economic Burden of Hookworm
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data collection methods. It should be noted that there is some uncertainty in infection intensity
thresholds, as they are based on limited data. Additionally, these thresholds would ideally vary
for different hookworm species. For example, Ancylostoma duodenale causes greater blood loss
than Necator americanus[41] so it would require fewer A. duodenale worms to cause the same
blood loss as an N. americanus infection. However, as A. duodenale causes less than 15% of the
global hookworm burden[42–44], our model did not differentiate between hookworm species.
Additionally, while a few studies have estimated the impact of anemia on worker productivity
[22], the true impact is not well understood or quantified. Many variations between studies
make them difficult to compare (e.g., geographically focal, involve very specific populations,
productivity loss definitions vary, studies are older, measure of productivity and length of time
vary) and generalizability is a concern. Other difficulties to measuring productivity losses
include underlying and/or concomitant health conditions that may also affect productivity and
a lack of studies designed to measure the impact of hookworm infection directly on productiv-
ity (compared to hookworm-associated outcomes).
Our estimates may in fact be quite conservative. We did not consider other possible out-
comes of hookworm (e.g., wasting and impact on physical growth) as they are difficult to quan-
tify. When using the 2010 DW estimates, the weight for symptomatic intestinal nematode
infections was applied only to those with heavy intensity infection. We also considered disabil-
ity from cognitive impairment (when utilizing the 2004 disability weight estimates) and while
chronic hookworm infection can lead to cognitive impairment[1, 17, 41, 45, 46], there is some
controversy and uncertainty regarding the amount of cognitive impairment caused by hook-
worm. In fact, cognitive impairment was removed from the 2010 GBD estimates. Additionally,
we did not include the potential impact of long-term cognitive impairment through adulthood.
Some studies show that chronic hookworm in childhood reduces future earnings in adults[47]
and that school-based deworming can have a differential impact on future wages[48]. How-
ever, there is little data on the number of adults with long-term hookworm-associated cognitive
impairment, making it difficult to differentiate between cognitive impairment in active vs. past
infections, especially in endemic areas. Thus to remain conservative, we excluded this outcome.
The cost calculation using Method 3 is likely an underestimate as we did not account for those
who perform heavy manual labor, and their reduction in productivity due to anemia may be
greater. Also, estimating at the population level may have underestimated the true burden of
disease (i.e., infection intensity) that may result in areas with a higher prevalence (i.e., our M
was calculated at a country level and thus may underestimate the number of medium and
heavy intensity infection in high prevalence areas). This in turn would underestimate hook-
worm’s clinical outcomes. Countries for which there was no hookworm prevalence data and
where conditions are not suitable for hookworm, were not included in this study. However, it
is possible that there may be a small burden of hookworm in these countries.
Human hookworm infection results in a substantial economic and health burden globally,
which surpasses published estimates for other diseases. Adults bear most of the costs and while
the total economic burden is highest in the Western Pacific region, certain large countries that
are transitioning into the higher income bracket such Brazil and China, still face considerable
hookworm burden. Interventions (such as a vaccine or community-wide treatment) to reduce
the disease burden of hookworm among all age groups could have substantial impacts on this
burden.
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